Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

Solid 2-Year Data With ‘Unlocking’ Coronary Stent: BIOADAPTOR RCT

News Conference News EuroPCR 2024

Solid 2-Year Data With ‘Unlocking’ Coronary Stent: BIOADAPTOR RCT

Michael O'Riordan

May 28, 2024

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

News Conference News EuroPCR 2023

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

Michael O'Riordan

May 18, 2023

For Bifurcation Lesions, It’s OK to Start With Just One Stent: EBC Trials

News Conference News EuroPCR 2023

For Bifurcation Lesions, It’s OK to Start With Just One Stent: EBC Trials

May 17, 2023

Imaging in PCI for Patients at High Bleeding Risk: Data Point to Possibilities

News Conference News EuroPCR 2022

Imaging in PCI for Patients at High Bleeding Risk: Data Point to Possibilities

May 25, 2022

Intravascular Imaging Boosts Outcomes in Left Main PCI ROLEX

News Conference News EuroPCR 2022

Intravascular Imaging Boosts Outcomes in Left Main PCI: ROLEX

Michael O'Riordan

May 18, 2022

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

News Conference News EuroPCR 2022

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

Yael L. Maxwell

May 17, 2022

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

News Conference News EuroPCR 2021

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

May 24, 2021

Provisional Stenting Noninferior to Planned Two-Stent Strategy for Left Main Disease: EBC MAIN

News Conference News EuroPCR 2021

Provisional Stenting Noninferior to Planned Two-Stent Strategy for Left Main Disease: EBC MAIN

May 21, 2021

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

News Conference News EuroPCR 2021

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

May 19, 2021

DynamX Bioadaptor Provides Promising Preliminary Results for De Novo Coronary Lesions

News Conference News EuroPCR 2020

DynamX Bioadaptor Provides Promising Preliminary Results for De Novo Coronary Lesions

June 30, 2020

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

News Conference News EuroPCR 2019

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Michael O'Riordan

May 27, 2019

Firehawk Stent Still Holds Up Well to Xience at 2 Years: TARGET All Comers

News Conference News EuroPCR 2019

Firehawk Stent Still Holds Up Well to Xience at 2 Years: TARGET All Comers

May 23, 2019

Ultrathin Struts Show Strength in Small Vessels: BIO-RESORT at 3 Years

News Conference News EuroPCR 2019

Ultrathin Struts Show Strength in Small Vessels: BIO-RESORT at 3 Years

May 21, 2019

DES Slightly Edge Out DCBs in Treatment of In-Stent Restenosis: Meta-analysis

News Conference News EuroPCR 2018

DES Slightly Edge Out DCBs in Treatment of In-Stent Restenosis: Meta-analysis

May 30, 2018

DCBs for CAD in Certain Patients With Large Vessel De Novo Disease? DEBUT Says Yes

News Conference News EuroPCR 2018

DCBs for CAD in Certain Patients With Large Vessel De Novo Disease? DEBUT Says Yes

May 25, 2018

Slimmest Stent to Date Looks Promising in Small Study

News Conference News EuroPCR 2017

Slimmest Stent to Date Looks Promising in Small Study

May 19, 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Conference News EuroPCR 2015

Evolving DES Technology May Benefit Diabetic Patients

May 19, 2015

News Conference News EuroPCR 2014

BABILON: Drug-Eluting Balloon a Risky Choice for Treating Bifurcation Lesions

May 21, 2014

News Conference News EuroPCR 2014

Despite Some Good News, Dedicated Stents Fail to Surpass Standard Care for Bifurcation Lesions

May 20, 2014

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.